Salute e Benessere

The Board Systemair resolves on share buyback

The buyback may comprise a maximum of 320,000 shares on one or several occasions and shall be carried out on Nasdaq Stockholm in accordance with applicable rules. The repurchase will be made at a price per share within the trading range registered at the given time. Payment for the shares will be made in cash. Reporting will be carried out through Nasdaq Stockholm in accordance with applicable regulations. The buyback may comprise a maximum of 320,000 shares on one or several occasions and...
PR Newswire
02/09/2025

Mass Spectrometry Market Size to Reach USD 10.13 Billion by 2030, Fueled by AI…

Rising Demand in Biologics Rising Demand in Biologics With the shift toward monoclonal antibodies and cell-based therapies, demand for advanced mass spectrometry systems is growing. Hybrid platforms that simplify protein characterization are set to drive strong market growth. Stricter Food-Safety Oversight New US and European regulations are accelerating instrument upgrades. Emerging tools like E-LEI-MS now enable real-time pesticide detection in minutes, cutting traditional...
PR Newswire
02/09/2025

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a…

Zymeworks Inc.(Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced its decision to voluntarily discontinue clinical development of ZW171, a T cell engager designed to target gynecological, thoracic, and digestive system cancers.ZW171 is designed to address cancers driven by...
Nasdaq GlobeNewswire
02/09/2025

Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery…

Cyclic Peptides: Bridging Small Molecules and Biologics Cyclic Peptides: Bridging Small Molecules and Biologics Cyclic peptides are increasingly recognized as an attractive drug modality to tackle traditionally "undruggable" targets. They combine the oral potential of small molecules with the structural advantages of biologics, enabling new approaches for protein–protein interactions and complex receptors. At the same time, they present key challenges: oral bioavailability is not…
PR Newswire
02/09/2025

European Infection Control Market worth US$20.58 billion by 2030 with 6.6% CAGR…

Browse in-depth TOC on "European Infection Control Market" Browse in-depth TOC on "European Infection Control Market" 468 - Tables 47 - Figures 476 - Pages By sterilization products & services,the sterilization products & services segment is further classified into sterilization equipment, contract sterilization services, and consumables & accessories. The sterilization equipment segment accounted for the largest share of the European infection control market…
PR Newswire
02/09/2025

EQT Life Sciences Leads USD 44 Million Series B Financing in Cyted Health to…

Cyted's technology has already demonstrated significant success across the UK's National Health Service, completing over 35,000 tests and building a robust portfolio of peer-reviewed publications proving unmatched patient acceptability and real-world clinical impact. Cyted's technology has already demonstrated significant success across the UK's National Health Service, completing over 35,000 tests and building a robust portfolio of peer-reviewed publications proving unmatched patient...
PR Newswire
02/09/2025

Nuffield Holdings Welcomes Strategic Shareholders to Drive Next Phase of…

Experienced and Visionary Partners Experienced and Visionary Partners MrLiu Songis the Founder and CEO of In Group Holdings Pte Ltd and Kamall International Pte Ltd. With over a decade of experience in sectors including real estate, mining, financial services, trade, and healthcare, his leadership has helped shape cross-border enterprises acrossAsia. His investment holding company, headquartered inSingapore, plays an active role in advancing sustainable and technology-driven...
PR Newswire
02/09/2025

Hemex expands Global Clinical Network Alliance to strengthen end-to-end CRO…

A newly established global alliance integrating specialized expertise in oncology, medical imaging, patient recruitment as well as pharmacokinetics and pharmacodynamics studiesComprehensive access to international trial networks, region-specific expertise, and diverse patient populationsSupported by a team of over 130 experienced professionals and a Quality Assurance team with a demonstrated history of successful inspections by major regulatory authorities worldwideLIESTAL, Switzerland, Sept...
Nasdaq GlobeNewswire
02/09/2025

Karo Healthcare strengthens its portfolio of skin health brands in Northern…

Karo will be acquiring an established business that includes the ACO (including Cosmica, Canoderm, Cliniderm, and Miniderm), Biodermal, Emolium, and Iwostin brands — each with strong brand heritage, high consumer trust, and a solid scientific foundation. The portfolio spans products across Face, Body, and Sun care categories, as well as medicated skin health brands. Karo will be acquiring an established business that includes the ACO (including Cosmica, Canoderm, Cliniderm, and Miniderm),...
PR Newswire
02/09/2025

OMass Therapeutics Enters into Exclusive Collaboration and License Agreement…

Collaboration leverages OMass’ Odyssion TMplatform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel diseaseOMass to receive $20 million upfront payment, with potential for more than $400 million in additional milestone payments, as well as tiered royalties on net salesOxford, United Kingdom – 2 ndSeptember 2025 –OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly...
Nasdaq GlobeNewswire
02/09/2025

Global Cancer Diagnostics Market to Hit USD 215 Billion by 2035, Growing at…

(Sample reports are a great way to test our in-depth reports or study before you make a purchase) (Sample reports are a great way to test our in-depth reports or study before you make a purchase) Key Takeaways: Top Key Players in The Global Cancer Diagnostics Market: To Know an Additional List of Key Players, Request Here to Download a Free Report PDF Brochure: https://www.vantagemarketresearch.com/cancer-diagnostics-market-2335/request-sample Market Overview &...
PR Newswire
02/09/2025

Coloplast A/S - Coloplast presents new 5-year strategy, Impact4

The new 5-year strategy, Impact4, will be presented today at the company’s Capital Markets Day 2025 TheImpact4strategy puts customers at the centre of everything we do and sets an ambitious goal for the company – to help 4 million people in the long-term. WithImpact4, we focus on four strategic priorities which are essential to our success and value creation:Grow through innovative customer offerings, by setting the standard of care and driving strong customer centricity...
Nasdaq GlobeNewswire
02/09/2025

CHARM Therapeutics raises $80 million in Series B financing to advance…

New investors NEA and SR One lead round alongside existing investors OrbiMed, F-Prime, NVIDIA and Khosla VenturesCHARM’s AI-designed menin inhibitor overcomes resistance mutations with the potential to deliver superior efficacy, durability and safety; clinical development expected to start 1Q 26Oncology leadership strengthened with appointment of former Syndax CEO Briggs Morrison, M.D. and Kim Blackwell, M.D. as non-executive directors of the boardLONDON – 2 September 2025--...
Nasdaq GlobeNewswire
02/09/2025

Coloplast A/S - Announcement no. 07/2025 - Coloplast announces new financial…

In relation to the launch of Coloplast’s new 5-year strategy, Impact4,the company announces a new financial ambition with organic revenue CAGR of 7-8% until FY 2029/30, growth in absolute EBIT* in line with or above revenue growth over the period and Return on Invested Capital (ROIC) of more than 20% in FY 2029/30. At its Capital Markets Day on 2 September 2025, Coloplast will present a new 5-year strategy,Impact4. In relation to the strategic update, Coloplast is providing a new...
Nasdaq GlobeNewswire
02/09/2025

ONWARD Medical Demonstrates Commercial Traction and Advances Pipeline in the…

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)EINDHOVEN, The Netherlands, Sept.02, 2025(GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announces its results for the first half of 2025:...
Nasdaq GlobeNewswire
02/09/2025

Pharming Group appoints Kenneth Lynard as Chief Financial Officer

Leiden, the Netherlands, September 2, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the appointment of Kenneth Lynard as Chief Financial Officer (CFO), effective October 1, 2025. Mr. Lynard is a seasoned finance executive with over 20 years of global leadership experience in the life sciences industry, recognized for driving financial and operational transformation across complex, multinational organizations. His appointment follows...
Nasdaq GlobeNewswire
02/09/2025

Sandstone Easydrip™ Plus Pen Needles Debut in Uzbekistan--Enhancing Daily…

Easydrip™ Plus uses a large‑platform hub for steadier grip and control. A thin‑wall, polished multi‑facet needle supports smooth, gentle insertion and reliable flow, helping reduce anxiety around frequent self‑injections and improving adherence. Easydrip™ Plus uses a large‑platform hub for steadier grip and control. A thin‑wall, polished multi‑facet needle supports smooth, gentle insertion and reliable flow, helping reduce anxiety around frequent self‑injections and improving adherence...
PR Newswire
02/09/2025

LOTTE BIOLOGICS establishes contract manufacturing partnership with a leading…

The partnership covers a late-stage Phase 3 program that is advancing into multiple new indications, and extends to commercial supply following potential regulatory approvals. By aligning with its partner's meaningful pipeline expansion into new therapeutic areas, LOTTE BIOLOGICS will be playing a pivotal role in supporting patient access to innovative medicines. The partnership covers a late-stage Phase 3 program that is advancing into multiple new indications, and extends to commercial…
PR Newswire
02/09/2025

TLR7/8 Agonists Market to Witness Accelerated Expansion Across the 7MM through…

TLR 7/8 Agonists Market Summary TLR 7/8 Agonists Market Summary Discover which indication is expected to grab the major TLR 7/8 agonists market share @TLR 7/8 Agonists Market Report Key Factors Driving the Growth of the TLR 7/8 Agonists Market Rising Prevalence of Cancer and Infectious Diseases The increasing global incidence of cancer and infectious diseases has heightened the demand for innovative therapeutic options. TLR7/8 agonists, which activate innate immune...
PR Newswire
01/09/2025

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…

Disclosure of Share Capital and Voting Rights Outstandingas of July 31, 2025(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Paris, France (September 1, 2025 - 6:00 pm)– As of July 31, 2025, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks down as...
Nasdaq GlobeNewswire
01/09/2025

Oxurion confirms progress in negotiations related to its treasury…

Leuven, BELGIUM – September 1, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that negotiations with Atlas Special Opportunities regarding the financing agreement are progressing constructively. The company expects to close the transaction before September 25, 2025…
Actusnews Wire
01/09/2025

Oxurion bevestigt de vooruitgang van de onderhandelingen over haar strategie…

Leuven, BELGIË – 1 september 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, kondigt aan dat de onderhandelingen met Atlas Special Opportunities over de financieringsovereenkomst constructief verlopen. De vennootschap verwacht de transactie vóór 25 september 2025 af te ronden…
Actusnews Wire
01/09/2025

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II…

Leuven, BELGIUM – September 1, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a transparency notification on August 28, 2025, from Atlas Special…
Actusnews Wire
01/09/2025

Idorsia furthers the science of sleep and insomnia at World Sleep 2025

Allschwil, Switzerland – September 1, 2025Idorsia Ltd (SIX: IDIA) continues its commitment to furthering the science of sleep and insomnia with a symposium and eight poster presentations at World Sleep 2025, a global scientific congress bringing the best of sleep medicine and research, in Singapore from September 5-10, 2025.Idorsia’s scientific poster presentations at World Sleep 2025: Real-world data assessment of abuse potential of insomnia therapiesA study to examine the real-world...
Nasdaq GlobeNewswire
01/09/2025
Altri  Comunicati